Jaffetilchin Investment Partners Has Upped Its Citigroup (C) Holding by $679,896; Stock Value Rose; Palo Alto Investors Has Boosted Its Holding in Biomarin Pharmaceutical (BMRN) as Stock Price Declined

January 1, 2018 - By Adrian Erickson

Jaffetilchin Investment Partners Llc increased its stake in Citigroup Inc (C) by 140.94% based on its latest 2017Q3 regulatory filing with the SEC. Jaffetilchin Investment Partners Llc bought 9,443 shares as the company’s stock rose 1.55% with the market. The institutional investor held 16,143 shares of the major banks company at the end of 2017Q3, valued at $1.17M, up from 6,700 at the end of the previous reported quarter. Jaffetilchin Investment Partners Llc who had been investing in Citigroup Inc for a number of months, seems to be bullish on the $196.74B market cap company. The stock decreased 0.89% or $0.67 during the last trading session, reaching $74.41. About 10.07M shares traded. Citigroup Inc. (NYSE:C) has risen 35.60% since January 1, 2017 and is uptrending. It has outperformed by 18.90% the S&P500.

William Leland Edwards increased its stake in Biomarin Pharmaceutical Inc (BMRN) by 2.26% based on its latest 2017Q3 regulatory filing with the SEC. Palo Alto Investors Llc bought 53,800 shares as the company’s stock declined 0.71% while stock markets rallied. The hedge fund run by William Leland Edwards held 2.44M shares of the major pharmaceuticals company at the end of 2017Q3, valued at $226.95 million, up from 2.38M at the end of the previous reported quarter. Palo Alto Investors Llc who had been investing in Biomarin Pharmaceutical Inc for a number of months, seems to be bullish on the $15.66B market cap company. The stock decreased 1.45% or $1.31 during the last trading session, reaching $89.17. About 799,380 shares traded. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has risen 5.29% since January 1, 2017 and is uptrending. It has underperformed by 11.41% the S&P500.

Among 37 analysts covering Citigroup Inc. (NYSE:C), 19 have Buy rating, 3 Sell and 15 Hold. Therefore 51% are positive. Citigroup Inc. had 106 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of Citigroup Inc. (NYSE:C) has “Buy” rating given on Monday, August 24 by SunTrust. Oppenheimer maintained Citigroup Inc. (NYSE:C) rating on Friday, October 16. Oppenheimer has “Outperform” rating and $72 target. The rating was upgraded by Guggenheim on Monday, November 30 to “Buy”. As per Monday, March 14, the company rating was maintained by Barclays Capital. Goldman Sachs downgraded Citigroup Inc. (NYSE:C) rating on Friday, September 16. Goldman Sachs has “Neutral” rating and $50 target. Nomura maintained Citigroup Inc. (NYSE:C) rating on Monday, July 17. Nomura has “Buy” rating and $78 target. The firm earned “Outperform” rating on Wednesday, April 5 by Keefe Bruyette & Woods. The stock of Citigroup Inc. (NYSE:C) has “Equal-Weight” rating given on Monday, October 26 by Morgan Stanley. The firm earned “Buy” rating on Friday, July 14 by BMO Capital Markets. RBC Capital Markets maintained Citigroup Inc. (NYSE:C) rating on Friday, October 13. RBC Capital Markets has “Outperform” rating and $79 target.

Investors sentiment increased to 1.35 in 2017 Q3. Its up 0.25, from 1.1 in 2017Q2. It improved, as 56 investors sold C shares while 400 reduced holdings. 125 funds opened positions while 492 raised stakes. 2.04 billion shares or 0.42% more from 2.03 billion shares in 2017Q2 were reported. American (D B A Uas Asset Management) has invested 2.41% in Citigroup Inc. (NYSE:C). Fiera stated it has 818,832 shares or 0.28% of all its holdings. Howe & Rusling invested 0.01% of its portfolio in Citigroup Inc. (NYSE:C). Confluence Wealth Ltd Liability Corp stated it has 6,896 shares or 0.25% of all its holdings. Eagle Mgmt Llc invested 6.23% in Citigroup Inc. (NYSE:C). Uss Management Limited has invested 1.94% in Citigroup Inc. (NYSE:C). Brinker Capital has 0.29% invested in Citigroup Inc. (NYSE:C). Randolph Company accumulated 1.96% or 145,325 shares. Kemnay Advisory has 0.35% invested in Citigroup Inc. (NYSE:C) for 11,259 shares. Cambiar Ltd Liability Co has 0.93% invested in Citigroup Inc. (NYSE:C). Westover Advisors Limited Liability Corp accumulated 58,863 shares. Moreover, Carnegie Capital Asset Mngmt Limited Liability Company has 0.18% invested in Citigroup Inc. (NYSE:C). Wafra Investment Advisory Group Inc Ny has 0.83% invested in Citigroup Inc. (NYSE:C). Horan Cap Advisors Limited owns 1,004 shares or 0.04% of their US portfolio. Victory Capital Management Incorporated owns 77,014 shares.

Jaffetilchin Investment Partners Llc, which manages about $401.38M and $424.32 million US Long portfolio, decreased its stake in Ulta Beauty Inc (NASDAQ:ULTA) by 2,112 shares to 901 shares, valued at $204,000 in 2017Q3, according to the filing. It also reduced its holding in Ishares Tr (EFA) by 4,903 shares in the quarter, leaving it with 12,686 shares, and cut its stake in Western Alliance Bancorp (NYSE:WAL).

Since August 4, 2017, it had 0 insider purchases, and 2 insider sales for $3.05 million activity. $2.70 million worth of Citigroup Inc. (NYSE:C) was sold by Aristeguieta Francisco.

Investors sentiment decreased to 1.13 in 2017 Q3. Its down 0.13, from 1.26 in 2017Q2. It dropped, as 40 investors sold BMRN shares while 116 reduced holdings. 45 funds opened positions while 132 raised stakes. 171.51 million shares or 2.04% more from 168.09 million shares in 2017Q2 were reported. Wells Fargo And Mn owns 670,839 shares or 0.02% of their US portfolio. 13,820 are owned by Platinum Mngmt Limited. Moreover, Pub Employees Retirement Association Of Colorado has 0.02% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Temasek Holdings (Private) Limited holds 1.88% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 3.47 million shares. Quantum Mngmt holds 2.09% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 95,237 shares. Public Employees Retirement Systems Of Ohio invested in 106,662 shares or 0.05% of the stock. Cibc Mkts has invested 0.01% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). 3,023 are held by Jefferies Grp Ltd. Seatown Pte Ltd has invested 0.11% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). D E Shaw And Inc has 91,792 shares. Moreover, Exane Derivatives has 0% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). State Of Alaska Department Of Revenue has 5,611 shares for 0.03% of their portfolio. Caisse De Depot Et Placement Du Quebec holds 4,100 shares or 0% of its portfolio. Hightower Advisors Limited Com accumulated 0% or 2,587 shares. Tang Mngmt Ltd Company holds 90,215 shares.

Among 27 analysts covering BioMarin Pharmaceutical (NASDAQ:BMRN), 20 have Buy rating, 0 Sell and 7 Hold. Therefore 74% are positive. BioMarin Pharmaceutical had 76 analyst reports since August 5, 2015 according to SRatingsIntel. Stifel Nicolaus maintained the shares of BMRN in report on Thursday, August 3 with “Buy” rating. Wedbush maintained BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on Wednesday, December 20 with “Buy” rating. The firm earned “Hold” rating on Wednesday, November 15 by Wedbush. The rating was initiated by BMO Capital Markets with “Outperform” on Thursday, April 7. The stock has “Buy” rating by Stifel Nicolaus on Friday, October 27. Credit Suisse maintained it with “Buy” rating and $124.0 target in Thursday, October 19 report. The company was maintained on Friday, October 6 by Morgan Stanley. The rating was maintained by Deutsche Bank on Thursday, July 13 with “Buy”. On Friday, October 2 the stock rating was initiated by Raymond James with “Outperform”. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) earned “Overweight” rating by Barclays Capital on Friday, August 5.

Palo Alto Investors Llc, which manages about $1.30B and $2.37B US Long portfolio, decreased its stake in Sage Therapeutics Inc (NASDAQ:SAGE) by 245,774 shares to 787,251 shares, valued at $49.05 million in 2017Q3, according to the filing. It also reduced its holding in United Therapeutics Corp Del (NASDAQ:UTHR) by 104,665 shares in the quarter, leaving it with 1.76 million shares, and cut its stake in Abiomed Inc (NASDAQ:ABMD).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: